254 filings
Page 5 of 13
8-K
ylkf7es0twkrnj6
3 Jan 22
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy
8:08am
8-K
jnzqnlohz1guxuoc
17 Nov 21
Other Events
7:30am
8-K
yzgi311eraf5
15 Oct 21
Departure of Directors or Certain Officers
4:36pm
8-K
f43vfu6 o4f
29 Sep 21
Departure of Directors or Certain Officers
4:17pm
8-K
bz5srbybpy7sqsjow3fo
28 Sep 21
Departure of Directors or Certain Officers
4:17pm
8-K
ucggtatgk m2
12 Jul 21
Other Events
8:14am
8-K
l8bjwuc78nrjbqcgy9
28 Jun 21
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy
4:22pm
8-K
feyiybm5l0sgpyu
13 May 21
Other Events
4:58pm
DEFA14A
5wq 1r1wn472rs5
30 Apr 21
Additional proxy soliciting materials
4:11pm
8-K
hhtiki32
25 Mar 21
Departure of Directors or Certain Officers
4:24pm
8-K
73w47uzs8q1lj2woio
9 Mar 21
Entry into a Material Definitive Agreement
9:06am
8-K
56b63 z9p3
2 Mar 21
Other Events
4:44pm
424B5
e2gdhuhd691wchefmp93
10 Feb 21
Prospectus supplement for primary offering
4:32pm
8-K
yzhpy hfq
9 Feb 21
Genprex, Inc. Announces $25 Million
4:59pm
8-K
rlm62ede0gr
28 Jan 21
Other Events
4:30pm